Get 50% OFF This Summer!
Astec Lifesciences
No Data Available
Investor Sentiment
Astec Lifesciences Share price and Fundamental Analysis
Key Metrics
Included In
Stock Returns
CAGR
Revenue Growth
Net Profit Growth
Operating Profit Growth
Dividend Growth
Stock Returns CAGR
Stock Heatmap
No Stocks
Smart Score
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
Technicals
Returns Calculator
If you would have investedResearch Report
No Research Report
Corporate Action
Financials
Key Ratios
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
Dividend History
5 Year FactSheet
Documents
No Data Available
News
Astec Lifesciences Management and History
Company Management
Unlock Management Data
See Detailed Analysis & Insights
Company History
Astec LifeSciences Ltd is a producer of agrochemicals and pharmaceutical intermediates. The company manufactures a wide range of Agrochemical active ingredients and pharmaceutical intermediates. They are having manufacturing facilities located at two locations in Maharashtra, India comprising of three units viz. one unit at Dombivli, Maharashtra and two units at Mahad, Maharashtra (Unit 1 and Unit 2). They are exporting their products to East Asia, Europe, Middle East, and USA.
The business of the company comprises of the two major segments, namely Agrochemicals and Pharmaceuticals. Under the Agrochemical segment, the company manufactures active ingredients, intermediates and formulations. Active ingredients are sold to crop protection formulators. Intermediates are supplied to technical grade product manufacturers. Formulations are sold in bulk quantities to companies engaged in retail marketing. Under the Pharmaceutical segment, the company carries out manufacturing of intermediates which are supplied to Active Pharma Ingredients (API) manufacturers.
Astec LifeSciences Ltd was incorporated on January 25, 1994 as a private limited company with the name Urshila Traders Pvt Ltd. The company was originally promoted by Reena Bagai and Avita Fernandes. Their shareholding was purchased by Ashok Hiremath and Pratap Garud on February 11, 1994. In August 19, 1994, the name of the company was changed from Urshila Traders Pvt Ltd to Astec Chemicals Pvt Ltd.
In August 1994, the company started their first manufacturing unit by acquiring a sick unit in Dombivli, Maharashtra having an installed capacity of 120 MT for the manufacture of Dicap, a pharmaceutical intermediate. In May 2001, they were awarded ISO 9002 Certification by International Standards Certification Pty Limited, Australia.
In February 18, 2002, the company entered into an agreement with Behram Chemicals Pvt Ltd with a view to expand their operations for using and operating their manufacturing facilities located at Mahad in Maharashtra. Behram Chemicals Pvt Ltd was engaged in manufacture of chemicals and pesticides with installed capacity of 130 MT.
During the year 2003-04, the company expanded the total installed capacity of their units (Dombivli and Mahad) from 250 MT to 500 MT. In the year 2004, they acquired a plot of land located at Mahad, Maharashtra. In May 2005, they set up a new manufacturing facility as an Export Oriented Unit (as Unit 2), which is adjacent to Unit 1 with an installed capacity of 1000 MT. With the commissioning of Unit 2, the company's total installed capacity increased to 1500 MT.
In March 2006, the name of the company was changed from Astec Chemicals Pvt Ltd to Astec LifeSciences Pvt Ltd. In April 2006, the company was converted into public limited company and the name was changed to Astec LifeSciences Ltd. During the year 2006-07, the company further expanded their total capacities to 2000 MT. In January 2007, they established Astec Europe in Tournai, Belgium.
During the year 2007-08, the company increased the production capacity of Agro & Pharma Intermediates by 500 MT to 2500 MT In April 2007, Behram Chemicals Pvt Ltd became the subsidiary of the company by the acquisition of 65.63% equity by the company vide Share Purchase Agreement.
During the year 2008-09, the company increased the production capacity of Agro & Pharma Intermediates by 300 MT to 2800 MT. They established a relationship with a major multinational for supply of one of our products into the global supply chain.
During the year 2009-10, the company increased the production capacity of Agro & Pharma Intermediates by 350 MT to 3150 MT. They also introduced new measures to improve EHS performance. In December 2009, the company has bagged orders worth Rs 7 crore from Syngenta India and Nufarm, which are amongst the world's top ten largest agrochemical manufacturing companies.
In June 2010, the company entered into a long term mutually exclusive confidential contract to supply an herbicide to a multinational agrochemical major. In August 2010, the company acquired land in MIDC Mahad area admeasuring 40000 sq mtrs with a view to set up additional manufacturing facilities on the new site.
In August 27, 2010, the company's Chairman & Managing Director, Ashok V Hiremath was awarded Prestigious 'Business Excellence' Award by the 'Indo-Thai Entrepreneurs Summit' Bangkok, Thailand for his outstanding contribution towards progress and development of Indian Economy and Society.
The Company incorporated a 100% wholly owned subsidiary, Astec CropCare Pvt. Ltd. to start the business of trading in agrochemicals and pesticides formulations to sell products. It made investments to increase the capacity of its manufacturing facility and to improvc the quality of products in Mahad. Work was started on construction of new 40000 sq m site at Mahad in Apr' 11.
During the year 2012-13, the Company has set-up a new subsidiary namely, Comercializadora Agricola Agroastrachem Cia Ltda in Bagota, Columbia.
During period 2015-16, Godrej Agrovet Limited acquired 45.29% of the Equity Share Capital of the Company from its ex-Promoters through an off-market transaction on 12th October, 2015 and consequently, the Company became a subsidiary of Godrej Agrovet Limited with effect from 6th November, 2015. Godrej Agrovet Limited got listed on the Stock Exchanges, viz., BSE Limited and National Stock Exchange of India Limited on 16th October, 2017.
During Financial Year 2020-21, Company sold off its entire equity stake in Astec Europe Sprl (a 50.10% subsidiary of Company in Belgium, Europe), in terms of a Share Purchase Agreement executed on 31st August 2020. Accordingly, Astec Europe Sprl ceased to be a subsidiary of Company with effect from 1st September, 2020.
During the Financial Year 2021-22, Company also commissioned its new herbicide plant and completed first batch of CMO product. It commercialized two new CMO products and a new production process for an enterprise product.
In April 2023, Company inaugurated a state-of-the-art Research & Development (R&D) Centre, named 'Adi Godrej Centre for Chemical Research and Development' in Rabale, Maharashtra.
Astec Lifesciences Share Price
Astec Lifesciences share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Astec Lifesciences Market Cap
Market capitalization of Astec Lifesciences indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Astec Lifesciences is valued compared to its competitors.
Astec Lifesciences PE Ratio
Astec Lifesciences PE ratio helps investors understand what is the market value of each stock compared to Astec Lifesciences 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
Astec Lifesciences PEG Ratio
The PEG ratio of Astec Lifesciences evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Astec Lifesciences ROE (Return on Equity)
Return on Equity (ROE) measures how effectively Astec Lifesciences generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Astec Lifesciences ROCE (Return on Capital Employed)
Return on Capital Employed (ROCE) evaluates the profitability of Astec Lifesciences in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Astec Lifesciences Total Debt
Total debt of Astec Lifesciences shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
Astec Lifesciences Debt to Equity Ratio
The Debt-to-Equity (DE) ratio of Astec Lifesciences compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
Astec Lifesciences CAGR (Compound Annual Growth Rate)
CAGR shows the consistent growth rate of Astec Lifesciences over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Astec Lifesciences Technical Analysis
Technical analysis of Astec Lifesciences helps investors get an insight into when they can enter or exit the stock. Key components of Astec Lifesciences Technical Analysis include:
Support Levels (S1, S2, S3)
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
Resistance Levels (R1, R2, R3)
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Astec Lifesciences shares often struggle to rise above due to selling pressure.
Astec Lifesciences Dividends
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Astec Lifesciences ’s financial health and profitability.
Astec Lifesciences Bonus Shares
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Astec Lifesciences Stock Split
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
Astec Lifesciences Financials
The financials of Astec Lifesciences provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
Astec Lifesciences Profit and Loss Statements
The profit and loss statement of Astec Lifesciences highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Astec Lifesciences .
Astec Lifesciences Balance Sheet
The balance sheet presents a snapshot of Astec Lifesciences ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Astec Lifesciences Cashflow Statements
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App
SEBI REGISTERED RESEARCH ANALYST REGISTRATION NUMBER: INH000015729Disclaimer: "Investments in securities are subject to market risks. Read all the related documents carefully before investing." Receiving registration from SEBI and certification from NISM does not assure the performance of the intermediary or guarantee returns to investors in any manner. Compliance Email: [email protected]
Features
Portfolio Analysis
Screener
Stock compare
Buckets
Watchlist
Superstar Portfolio
Market
List of BSE200 Companies
List of NIFTY500 Companies
List of NIFTY NEXT 50 Companies
NIFTY Top gainers in 5 Days
NIFTY100 Most Active Stocks
NIFTY Top Gainers in 1 Month